Eric D Whitman
Overview
Explore the profile of Eric D Whitman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
906
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Whitman E, Totev T, Jiang S, da Costa Jr. W, Grebennik D, Wang H, et al.
BMC Cancer
. 2024 Mar;
24(1):389.
PMID: 38539148
Background: The objective of this study was to describe real-world adjuvant therapy (AT) use by disease substage and assess determinants of treatment choice among patients with stage III melanoma. Methods:...
2.
Whitman E, Guenther J
J Surg Oncol
. 2022 Mar;
125(8):1343-1344.
PMID: 35353374
No abstract available.
3.
Welker J, Pulido J, Catanzaro A, Malvestutto C, Li Z, Cohen J, et al.
Lancet Infect Dis
. 2022 Mar;
22(5):611-621.
PMID: 35286843
Background: Non-antiviral therapeutic options are required for the treatment of hospitalised patients with COVID-19. CD24Fc is an immunomodulator with potential to reduce the exaggerated inflammatory response to tissue injuries. We...
4.
Whitman E, Koshenkov V, Gastman B, Lewis D, Hsueh E, Pak H, et al.
JCO Precis Oncol
. 2021 Sep;
5.
PMID: 34568719
Methods: An integrated 31-GEP (i31-GEP) neural network algorithm incorporating clinicopathologic features with the continuous 31-GEP score was developed using a previously reported patient cohort (n = 1,398) and validated using...
5.
Andtbacka R, Curti B, Daniels G, Hallmeyer S, Whitman E, Lutzky J, et al.
J Clin Oncol
. 2021 Aug;
39(34):3829-3838.
PMID: 34464163
Purpose: We evaluated the activity of intratumoral Coxsackievirus A21 (V937) in 57 patients with unresectable stage IIIC or IV melanoma. Patients And Methods: In this multicenter, open-label, phase II study,...
6.
Sarnaik A, Hamid O, Khushalani N, Lewis K, Medina T, Kluger H, et al.
J Clin Oncol
. 2021 May;
39(24):2656-2666.
PMID: 33979178
Purpose: Effective treatment options are limited for patients with advanced (metastatic or unresectable) melanoma who progress after immune checkpoint inhibitors and targeted therapies. Adoptive cell therapy using tumor-infiltrating lymphocytes has...
7.
Ferretti A, Kula T, Wang Y, Nguyen D, Weinheimer A, Dunlap G, et al.
Immunity
. 2020 Oct;
53(5):1095-1107.e3.
PMID: 33128877
Developing effective strategies to prevent or treat coronavirus disease 2019 (COVID-19) requires understanding the natural immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We used an unbiased, genome-wide...
8.
Whitman E, Scherrer E, Ou W, Krepler C
Future Oncol
. 2020 May;
16(20):1441-1453.
PMID: 32410465
To determine outcomes of retreatment with anti-PD-1 monotherapy for melanoma. This retrospective study included adults with unresectable cutaneous melanoma who achieved stable disease (SD) or better after anti-PD-1 monotherapy and...
9.
Liu F, Ou W, Diede S, Whitman E
Medicine (Baltimore)
. 2019 Jul;
98(30):e16542.
PMID: 31348273
Pembrolizumab has been approved in the United States for treating advanced melanoma for >4 years. We examined real-world pembrolizumab use and associated outcomes in US oncology clinical practices, including patients...
10.
Whitman E, Liu F, Cao X, Diede S, Haiderali A, Abernethy A
Future Oncol
. 2018 Sep;
15(5):459-471.
PMID: 30251550
Aim: To describe recent evolution in treatment patterns and outcomes for advanced melanoma (AMel). Methods: This retrospective observational study analyzed de-identified electronic health record data from the Flatiron Health database...